SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006; 118: 30303044.
  • 2
    Bosch FX,Lorincz A,Munoz N,Meijer CJ,Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002; 55: 244265.
  • 3
    Clifford G,Franceschi S,Diaz M,Munoz N,Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24( suppl 3): S26S34.
  • 4
    Schiffman M,Castle PE,Jeronimo J,Rodriguez AC,Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007; 370: 890907.
  • 5
    Rousseau MC,Pereira JS,Prado JC,Villa LL,Rohan TE,Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis. 2001; 184: 15081517.
  • 6
    Liaw KL,Hildesheim A,Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis. 2001; 183: 815.
  • 7
    Mao C,Koutsky LA,Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006; 107: 1827.
  • 8
    Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of 4 randomised clinical trials. Lancet. 2007; 369: 18611868.
  • 9
    Koutsky LA,Ault KA,Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347: 16451651.
  • 10
    Pan American Health Organization (PAHO), Immunization Unit. Ad hoc meeting of experts on surveillance of HPV-associated diseases in the americas. PAHO Immunization Newsletter. December 2006: 14.
  • 11
    US Cancer Statistics Working Group. United States Cancer Statistics 1999-2003 Incidence and Mortality Web-based Report. Atlanta, Ga: US Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2007.
  • 12
    Cogliano V. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Human Papillomavirus [90]. Lyon, France: International Agency for Research on Cancer; 2007.
  • 13
    Dillner J,Arbyn M,Dillner L. Translational mini-review series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2007; 148: 199207.
  • 14
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14: 467475.
  • 15
    Ryerson AB,Peters ES,Coughlin SS, et al. Burden of potentially HPV-associated cancers of the oropharynx and oral cavity in the United States, 1998-2003. Cancer. 2008; 113( suppl 6): 000000.
  • 16
    Sturgis EM,Cinciripini PM. Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer. 2007; 110: 14291435.
  • 17
    American Association of Cancer Registries, Data Standards Committee. Subcommittee on Noninvasive Cervix Lesions, Working Group on Preinvasive Cervical Cancer Neoplasia and Population-based Cancer Registries: Final Subcommittee Report Rockville, MD, April 5-6, 1993.
  • 18
    HavenerLA,HultstromD, eds. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Eleventh Edition, Version 11.1. Springfield, Ill: North American Association of Central Cancer Registries; 2006. Available at: http://www.naaccr.org/filesystem/pdf/Volume%20II%20Version%2011.1.pdf. Accessed on July 16, 2008.
  • 19
    Sherman ME,Lorincz AT,Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003; 95: 4652.
  • 20
    Carreon JD,Sherman ME,Guillen D, et al. CIN2 is a much less reproducible and less valid diagnosis than CIN3: results from a histological review of population-based cervical samples. Int J Gynecol Pathol. 2007; 26: 441446.
  • 21
    Bosch FX,Manos MM,Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst. 1995; 87: 796802.
  • 22
    Cox JT,Schiffman M,Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol. 2003; 188: 14061412.
  • 23
    Zuna RE,Allen RA,Moore WE,Mattu R,Dunn ST. Comparison of human papillomavirus genotypes in high-grade squamous intraepithelial lesions and invasive cervical carcinoma: evidence for differences in biologic potential of precursor lesions. Mod Pathol. 2004; 17: 13141322.
  • 24
    Wright TC,Kurman RJ,Ferenczy A. Precancerous lesions of the cervix. In: KurmanRJ, ed. Blaustein's Pathology of the Female Genital Tract,5th ed. New York, NY: Springer- Verlag; 2001: 253324.
  • 25
    Copeland G,Datta SD,Spivak G,Garvin AD,Cote ML. Total burden and incidence of in situ and invasive cervix cancer in Michigan, 1985-2003. Cancer. 2008; 113( 10 suppl): 29462954.
  • 26
    Goodman MT,Hernandez BY,Hewitt S, et al. Tissues from population-based cancer registries: a novel approach to increasing research potential. Hum Pathol. 2005; 36: 812820.
  • 27
    Linkins RW. Immunization registries: progress and challenges in reaching the 2010 national objective. J Public Health Manag Pract. 2001; 7: 6774.
  • 28
    National Vaccine Advisory Committee. Development of Community and State-based Immunization Registries: Report of the National Vaccine Advisory Committee (NVAC). Atlanta, Ga: US Department of Health and Human Services, CDC; 1999.
  • 29
    Castle PE,Solomon D,Saslow D,Schiffman M. Commentary: predicting the effect of successful human papillomavirus vaccination on existing cervical screening programs in the United States. Cancer. 2008; 113( 10 suppl): 30313035.
  • 30
    Mayrand MH,Duarte-Franco E,Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 15791588.
  • 31
    Khan MJ,Castle PE,Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97: 10721079.
  • 32
    Goldie SJ,Kim JJ,Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol. 2004; 103: 619631.
  • 33
    Goldie SJ,Kohli M,Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004; 96: 604615.
  • 34
    Tiro JA,Saraiya M,Jain N, et al. Human papillomavirus and cervical cancer behavioral surveillance in the United States. Cancer. 2008; 113( 10 suppl): 30133030.
  • 35
    Centers for Disease Control and Prevention, National Cancer Institute. State Cancer Profiles. Bethesda, Md: National Cancer Institute; 2007. Available at: http://statecancerprofiles.cancer.gov/. Accessed on July 16, 2008.
  • 36
    Lehtinen M,Herrero R,Mayaud P, et al. Chapter 28: studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine. 2006; 24( suppl 3): S233S241.
  • 37
    Wright TCJr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 Consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis. 2007; 11: 223239.